Due to the onset of the regression in Pt9 at the end of the treatment, it is very likely that the PD-L1- and PD-L2-specific T-cell responses induced by the vaccines have reinstated the tumor immune surveillance in this patient. This evidence concerns the gene PDCD1LG2 and neoplasm.